Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06049667 | A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies | unknown | Phase 1 | 72 | Nanjing Chia-tai Tianqing PharmaceuticalINDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04187118 | Quality of Life in Lymphoma Patients One Year Post-chemotherapy(QUALIPSO-L) | unknown | — | 600 | University Hospital, ToulouseOTHER | 1 | Sep 21, 2023 |
| clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05801835 | A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection | unknown | N/A | 36 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06041815 | Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies | unknown | — | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT03709914 | PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)(Pediatric_PK) | unknown | Phase 1 | 21 | Nabriva Therapeutics AGINDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01004640 | Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial | unknown | — | 60 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05979948 | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia(CZ-WM01) | unknown | Phase 2 | 60 | Shanghai Changzheng HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06037239 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05629260 | The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation | unknown | — | 300 | Peking University People's HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06026995 | Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells | unknown | Phase 4 | 174 | Chongqing University Cancer HospitalOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06027853 | Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03759093 | CURATE.AI Optimized Modulation for Multiple Myeloma | unknown | Phase 2 / Phase 3 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05174338 | Cardiac Amyloidosis Registry Study(CARS) | unknown | — | 5,000 | Cedars-Sinai Medical CenterOTHER | 2 | Sep 6, 2023 | clinicaltrials |
| NCT05296772 | Phase 1 First-in-human Study of JS014 | unknown | Phase 1 | 60 | Anwita BiosciencesINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT06008405 | Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy | unknown | Phase 1 | 48 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05896007 | Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT | unknown | Phase 2 | 29 | Ruijin HospitalOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05926427 | Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement | unknown | Phase 2 | 25 | Ruijin HospitalOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05973162 | Effects of Virtual Reality in Pediatric Burn Patients | unknown | N/A | 30 | Riphah International UniversityOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05963347 | Go-CHOP as the Frontline Therapy for PTCL | unknown | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 1, 2023 | clinicaltrials |
| NCT00900224 | Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia | unknown | — | 529 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT02229422 | A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)(GA101 & HDMP) | unknown | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06018324 | CloudCare in the Treatment of Type 1 Diabetes in Pediatrics | unknown | — | 600 | Diabeter Nederland BVOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06015464 | An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL | unknown | — | 81 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03490084 | Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma(PAMM-HAD1) | unknown | — | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04309981 | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. | unknown | Phase 1 / Phase 2 | 73 | Sara V. LatorreOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | unknown | Early Phase 1 | 12 | Changhai HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05784870 | A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors | unknown | Phase 3 | 168 | Zhongnan HospitalOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06007989 | Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)(CHIME) | unknown | — | 10 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT03962465 | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL(ALL-001) | unknown | Phase 1 | 36 | University of VirginiaOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)(AIM) | unknown | Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03331731 | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma(PLIMATH) | unknown | Phase 2 | 27 | Peter MacCallum Cancer Centre, AustraliaOTHER | 2 | Aug 21, 2023 | clinicaltrials |
| NCT05979792 | Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | unknown | Early Phase 1 | 35 | Zhao WeiliOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | unknown | N/A | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05995808 | Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests | unknown | N/A | 30 | Sohag UniversityOTHER | 0 | Aug 16, 2023 | clinicaltrials |
| NCT05758207 | Oral Complications in Hematological Malignancies | unknown | — | 100 | Assiut UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05993052 | Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms | unknown | — | 100 | Sohag UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05993065 | Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis. | unknown | — | 100 | Sohag UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05983172 | Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia | unknown | — | 1,500 | National Taiwan University HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05982756 | Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML | unknown | Phase 1 | 40 | Zhongnan HospitalOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05390528 | A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma(HLX301) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | unknown | Phase 1 / Phase 2 | 38 | Actinium PharmaceuticalsINDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05977387 | Pediatric Kidney Transplant(PeKiT) | unknown | — | 500 | Imagine InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05974085 | XPO-1 in Combination With RCHOP for DH/TH Lymphoma | unknown | Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05975164 | the Real World Study of Orelabrutinib in the Treatment of CLL/SLL | unknown | — | 50 | Shandong UniversityOTHER | 0 | Aug 3, 2023 | clinicaltrials |
| NCT05005299 | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation(VICTORY) | unknown | Phase 1 | 18 | Melbourne HealthOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05871684 | A Combination Study of CAR-T Therapy in r/r B-NHL | unknown | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05967975 | Elastography and Treatment of Lymphoma | unknown | — | 44 | Assiut UniversityOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05968001 | Obinutuzumab in Chinese Real-world Patients With iNHL | unknown | — | 400 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970822 | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML | unknown | Phase 1 | 32 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 22, 2023source: clinicaltrials